Drug recall: CJC-1295, 2000 MCG/ML, 5 ML vial, The Guyer Institute of Molecular Medicine, Indianapolis, IN
Class II FDA enforcement event 86799. Recall start date: . Status in the FDA record: Ongoing.
Reason for recall, in the words of FDA
Lack of Assurance of Sterility: due to concerns with production processes which cannot assure sterility of products intended to be sterile.
Class II, in the words of FDA
a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Advanced Nutriceuticals, LLC started this drug recall on 30 Nov 2020. The firm address in the FDA record is in Indianapolis, IN. FDA put the recall in Class II. FDA event 86799 has 17 product records. The first FDA enforcement report date is 23 Dec 2020. The record gives the status Ongoing.
It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.
FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .
Distribution
In the words of FDA.
CA, CO, FL, IN, KY, OH, TX
Recalling firm
Advanced Nutriceuticals, LLC, Indianapolis, IN.
Recalling firm: The firm that the FDA record names for a recall.
FDA records how the recall started: Voluntary: Firm initiated.
Products
17 product records in the event.
| Recall number | Product | Quantity | Class | Status | Report date |
|---|---|---|---|---|---|
| D-0128-2021 | CJC-1295, 2000 MCG/ML, 5 ML vial, The Guyer Institute of Molecular Medicine, Indianapolis, IN | 6 vials | Class II | Ongoing | 23 Dec 2020 |
| D-0129-2021 | FGL, 10 MG/ML, 3 ML vial, The Guyer Institute of Molecular Medicine, Indianapolis, IN | 1 vial | Class II | Ongoing | 23 Dec 2020 |
| D-0130-2021 | PT-141, 10 MG/ML, 2 ML vial, The Guyer Institute of Molecular Medicine, Indianapolis, IN | 1 vial | Class II | Ongoing | 23 Dec 2020 |
| D-0131-2021 | AOD-9604, 1200 MCG/ML, 5 ML vial The Guyer Institute of Molecular Medicine, Indianapolis, IN | 3 vials | Class II | Ongoing | 23 Dec 2020 |
| D-0132-2021 | BPC-157, 2000 MCG/ML, 5 ML vial, The Guyer Institute of Molecular Medicine, Indianapolis, IN | 4 vials | Class II | Ongoing | 23 Dec 2020 |
| D-0133-2021 | THYMOSIN ALPHA, 2000 MCG/ML, 5 ML vial, The Guyer Institute of Molecular Medicine, Indianapolis, IN | 4 vials | Class II | Ongoing | 23 Dec 2020 |
| D-0134-2021 | IPAMORELIN, 2000 MCG/ML, 5 ML vial, The Guyer Institute of Molecular Medicine, Indianapolis, IN | 3 vials | Class II | Ongoing | 23 Dec 2020 |
| D-0135-2021 | GHRP, 2000 MCG/ML, 5 ML vial, The Guyer Institute of Molecular Medicine, Indianapolis, IN | 1 vial | Class II | Ongoing | 23 Dec 2020 |
| D-0136-2021 | NANDROLONE, 200 MCG/ML, 2 ML, The Guyer Institute of Molecular Medicine, Indianapolis, IN | 2 vials | Class II | Ongoing | 23 Dec 2020 |
| D-0137-2021 | B12 for Injection, 2 MG/ML, 10 ML vial, The Guyer Institute of Molecular Medicine, Indianapolis, IN | 1 vials | Class II | Ongoing | 23 Dec 2020 |
| D-0138-2021 | DSIP, 1000 MCG/ML, 5 ML vial, The Guyer Institute of Molecular Medicine, Indianapolis, IN | 1 vial | Class II | Ongoing | 23 Dec 2020 |
| D-0139-2021 | CEREBROLYSIN, 107.5 MG/ML, 10 ML vial, The Guyer Institute of Molecular Medicine, Indianapolis, IN | 1 vial | Class II | Ongoing | 23 Dec 2020 |
| D-0140-2021 | THYMOSIN BETA - 4, 2000 MCG/ML, 5 ML vial, The Guyer Institute of Molecular Medicine, Indianapolis, IN | 3 vials | Class II | Ongoing | 23 Dec 2020 |
| D-0141-2021 | GHK-CU, 10 MG/ML, 5 ML vial, The Guyer Institute of Molecular Medicine, Indianapolis, IN | 1 vial | Class II | Ongoing | 23 Dec 2020 |
| D-0142-2021 | HIGH DOSE B12, 10 MG/ML, 10 ML vial, The Guyer Institute of Molecular Medicine, Indianapolis, IN | 1 vials | Class II | Ongoing | 23 Dec 2020 |
| D-0143-2021 | LL-37, 2000 MCG/ML, 2 ML vial, The Guyer Institute of Molecular Medicine, Indianapolis, IN | 1 vial | Class II | Ongoing | 23 Dec 2020 |
| D-0144-2021 | Pentosan Polysulfate, 300 MG/ML, 5 ML vial, The Guyer Institute of Molecular Medicine, Indianapolis, IN | 1 vial | Class II | Ongoing | 23 Dec 2020 |
openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports.
Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.
Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.
Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.
Class II: The middle of the three FDA recall classes.
The event in context
- Drug events that started in 2020
- 342
- Share of these events in Class II
- 64%
- Product records in this event
- 17
- Events of the firm on the register
- 1
Official channels
- FDA enforcement report D-0128-2021The FDA record of the first product of this event.
- FDA: recalls, market withdrawals and safety alertsThe recall notices on the FDA site.
- FDA MedWatchThe FDA safety reporting program for drugs and medical devices.
Follow by RSS:Food, drug and device recallsFDA Class I recalls
Cite this page
Recall Register. FDA enforcement event 86799. https://recallregister.com/fda/ii/86799/. Source: openFDA enforcement reports. Data through .
Sources
- Source
- openFDA drug enforcement reports
- Licence
- CC0 1.0
- Export date
- 28 Sep 2026
- Newest FDA report date on the register
- 23 Sep 2026
FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.
Questions
- Where was the product distributed?
- The FDA record gives this distribution:
CA, CO, FL, IN, KY, OH, TX
- What quantity of product is in FDA event 86799?
- The event has 17 product records. The first record gives this quantity:
6 vials
- How did the recall start?
- The FDA record says:
Voluntary: Firm initiated
- How many drug recalls of 2020 have the same class?
- 64% of the 342 drug events that started in 2020 are in Class II.